Biogen: sellers take over post-earnings
Biogen stock rises 0.4% but sellers dominate the post-earnings session
Biogen: sellers take over post-earnings
Our view last week
Biogen eases back in the 190 area, down 1.8% this week heading straight into the July 29 earnings report. June's double bottom still holds and the rebound stays at 18%, but the technical picture is losing steam: weekly ADX is fading, MACD is deteriorating, and daily buyers keep the edge without really pushing. The stock is now boxed between the 20-day average and the daily VWMA, with the earnings event weighing on the timing of any fresh move.
This week's summary
Biogen's earnings report landed last week, and the market still hasn't picked a direction. Biogen stock closes the week up 0.4%, but sellers took clear control in the last session, with 82% of daily volume on the sell side. Weekly ADX keeps fading and the MACD has flipped into a bearish cross: the trend is losing steam. This week's technical analysis calls for watching the post-earnings follow-through closely.
IQS Phase
47
ordinary
Signal Strength
66
medium
Sizing
STANDARD
Ranking
#33 / 120
US stocks in progress
Trade P&L %
+4.91%
from signal to date, no stop loss
Rank position
ranks 33rd among the 120 Longs already running for US stocks in our ranking, with a signal strength of 66 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly -0.01% · monthly +1.89%
BIIB belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content